ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/11/2025
Locations: Research Site, Tucson, Arizona +213 locations
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Recruiting
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) de... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/11/2025
Locations: Arizona Cancer Center at UMC North/University Medical Center, Tucson, Arizona
Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
Recruiting
The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Local Institution - 0228, Fullerton, California +228 locations
Conditions: Sjögren's Syndrome
Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume
Recruiting
The purpose of this study is to evaluate whether pulmonary blood volume (PBV) derived from contrast echocardiography can serve as a non-invasive surrogate for invasive pulmonary artery wedge pressure (PAWP) during exercise. Also, to compare changes in PBV with exercise in patients with and without heart failure and pulmonary vascular disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Heart Failure, Pulmonary Vascular Disease
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
Recruiting
Alternatives For Girls (AFG's) EmpowHer curriculum is a program for youth who are 10-15 years of age. The curriculum is youth-co-led, and innovative (using online platforms and digitized presentation of material. EmpowHer addresses four adulthood preparation subjects (APS), such as parent-child communication, healthy relationships, adolescent development, and healthy life skills, and can be implemented as an after-school, in/out-of-school-time program.
Gender:
ALL
Ages:
Between 10 years and 15 years
Trial Updated:
08/11/2025
Locations: Alternatives For Girls, Detroit, Michigan
Conditions: Abstinence, Sex
Let's E.A.T.! (Eating With Assistive Technology): An Intervention to Support Children With Feeding Tubes and Tracheostomies
Recruiting
The overall objective of this proposal is to test an interdisciplinary intervention to support the transition to oral feeding for children with feeding tubes and tracheostomies. The investigators' model which combines in-home clinical assessments with virtual therapies may maximize the impact of expert interventionists. The investigators' central hypothesis is that children with feeding tubes and tracheostomies will have greater success than a control group when enrolled in a hybrid in-person/vi... Read More
Gender:
ALL
Ages:
3 years and below
Trial Updated:
08/11/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Feeding Tube, Children With Medical Complexity, Tracheostomy, Feeding Disorder, Infancy or Early Childhood
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Recruiting
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Alaska Womens Cancer Care, Anchorage, Alaska +76 locations
Conditions: Endometrial Cancer
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Recruiting
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 80 participants will be randomized.
Gender:
MALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/11/2025
Locations: Urology Associates of Mobile, Mobile, Alabama +49 locations
Conditions: Prostatic Neoplasm
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Recruiting
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Ad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/11/2025
Locations: The University of Texas at Dallas, Richardson, Texas
Conditions: Multiple Sclerosis, Relapsing-Remitting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
08/11/2025
Locations: Local Institution - 1029, Homewood, Alabama +382 locations
Conditions: Psychosis Associated With Alzheimer's Disease
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
Recruiting
The purpose of this preliminary research study is to see if patients discontinuing maintenance Herceptin and/or other anti-HER-2 treatments with monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission and to determine how long patients are able to stay in complete radiological remission without treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: University of Miami, Miami, Florida
Conditions: HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Recruiting
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2025
Locations: Arizona Oncology Associates, Tucson, Arizona +15 locations
Conditions: Multiple Myeloma